The United States of America, As Represented by the Secretary, Department of Health and Human Services

The Ohio State University

The United States of America Nih Division of Extramural Inventions and Technology Resources (deitr)

Danilo Perrotti

Ching-Shih Chen

John C Byrd

Natarajan Muthusamy

Paolo Neviani

James T Dalton

Ramasamy Santhanam

Frank Frissora

Xiaobin Zhao

Qing Liu

A method of inhibiting the growth of leukemic hematopoietic stem cells in a subject with leukemia is described. The method includes administering a therapeutically effective amount of a composition including a compound of formula I: I wherein Ris independently selected from hydrogen and methyl; Ris selected from the group consisting of 4,8-dimethyl-non-1-enyl, 4,8-dimethyl-nonyl, non-1-enyl, and nonanyl groups; X is a carboxyl, phosphonic, or sulfonic moiety, and n is an integer from 1 to 6, or a compound of Formula II: II wherein Ris a C-Calkyl or C-Calkoxy group; Ris independently selected from the group consisting of hydrogen, methoxy, and hydroxyl; and Ris an alkyl or cycloalkyl group; or a pharmaceutically acceptable salt thereof. 

Inhibition of leukemic stem cells by PP2A activating agents

The invention provides for methods of treating a mammal who has a BCR/ABL-mediated leukemia, including chronic myelogenous leukemia (CML), particularly the blast crisis stage of CML, Philadelphia-positive acute lymphoblastic leukemia (Ph'-ALL), and refractory leukemias. The invention also provides for compounds for the treatment of these leukemias and methods of identifying anti-leukemic agents.

Therapeutic agents for the treatment of leukemia

Methods&#x2014;for treatment and prevention of lymphoid malignancies, including, but not limited to acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell lymphoma, Acute Myeloid leukemia (AML), and mantle cell lymphoma (MCL). The methods include administration of a therapeutically effective amount of FTY720 (2-Amino-2-[2-(4-octylphenyl)ethyl]propane 1,3-diol hydrochloride) or a derivative, pharmaceutically acceptable salt thereof, or a prodrug thereof to a subject.

Therapeutic agents for the treatment of lymphoid malignancies

Growing community of inventors

Dublin, OH, United States of America

Danilo Perrotti